<DOC>
	<DOCNO>NCT00042497</DOCNO>
	<brief_summary>The objective determine safety efficacy dexosome immunotherapy patient Stage IV malignant melanoma</brief_summary>
	<brief_title>Immunotherapy With Autologous Dexosomes Patients With Stage IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients Stage IV metastatic melanoma 01 prior treatment metastatic disease . All patient must distant skin , subcutaneous , nodal metastasis ( M1a ) lung metastasis ( M1b ) , measurable disease , normal lactate dehydrogenase level , HLA type A1 , A2 , B35 . Patients must adequate organ function estimate life expectancy least 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
</DOC>